New Zealand markets open in 6 hours 11 minutes

Protagenic Therapeutics, Inc. (PTIX)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
0.9050-0.0330 (-3.52%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 4.03M
Enterprise value -823.52k
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.89
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.11

Trading information

Stock price history

Beta (5Y monthly) 0.32
52-week change 3-54.98%
S&P500 52-week change 322.55%
52-week high 32.2200
52-week low 30.6800
50-day moving average 31.2615
200-day moving average 31.1277

Share statistics

Avg vol (3-month) 314.13k
Avg vol (10-day) 315.19k
Shares outstanding 54.45M
Implied shares outstanding 64.55M
Float 83.22M
% held by insiders 121.83%
% held by institutions 117.53%
Shares short (14 Jun 2024) 49.12k
Short ratio (14 Jun 2024) 40.41
Short % of float (14 Jun 2024) 40.26%
Short % of shares outstanding (14 Jun 2024) 40.20%
Shares short (prior month 15 May 2024) 49.73k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 327 Jul 2016
Ex-dividend date 4N/A
Last split factor 21:4
Last split date 323 Mar 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-67.43%
Return on equity (ttm)-140.56%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -5.49M
Net income avi to common (ttm)-6.01M
Diluted EPS (ttm)-1.3700
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)2.42M
Total cash per share (mrq)0.55
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)5.53
Book value per share (mrq)0.48

Cash flow statement

Operating cash flow (ttm)-4.99M
Levered free cash flow (ttm)-3.35M